Browse News
Filter News
Found 108 articles
-
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
4/16/2024
Palisade Bio, Inc. announced today the successful completion of its analysis evaluating ex-vivo bioactivation of PALI-2108.
-
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
3/7/2024
Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board).
-
BioIVT to Showcase Leading Products for Toxicological Studies at the SOT ToxExpo 2024
3/7/2024
BioIVT today announced its presence and scientific contributions at the 2024 Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo.
-
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic
2/26/2024
Hoth Therapeutics, Inc. announced today that it has completed bioanalytical method development under its prior agreement with Altasciences and plans to further engage Altasciences to perform a key study of mouse blood and plasma analysis from samples collected in Hoth's sponsored scientific research conducted at NC State University.
-
Altasciences Appoints New General Manager, Clinical Operations
1/29/2024
Altasciences announced the appointment of James Brazeal as General Manager, Clinical Operations, at its clinical facility in Kansas City.
-
Altasciences Completes Expansion of New State-Of-The-Art Laboratory in Columbia, Missouri
10/31/2023
Altasciences is pleased to announce the completion of its laboratory facilities in Columbia, MO.
-
Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses
9/21/2023
Altasciences is pleased to have been chosen by Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) (“Virpax”), a company specializing in developing non-addictive products for pain management, PTSD, central nervous system (CNS) disorders, and viral barrier indications, to conduct preclinical studies in support of their development of quaternary ammonium palmitoyl glycol chitosan (GCPQ, under the trade name of AnQlar™).
-
Altasciences Completes Successful Phase I Trial of Ischemix’ Novel Compound for Treatment of Traumatic Brain Injury (TBI)
8/30/2023
Altasciences is pleased to have completed a Phase I trial on Ischemix, Inc.’s novel, proprietary cytoprotective drug candidate, CMX-2043, for the treatment of acute TBI.
-
Ischemix, Inc. Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury (TBI); Preparing for Conduct of Phase 2 Trial
8/25/2023
Ischemix, Inc., a privately-held company focused on developing cytoprotective therapeutics for serious medical conditions, today announced that it has completed an 80-subject Phase 1 clinical trial to evaluate safety, tolerability and pharmacokinetics of its drug candidate, CMX-2043, in healthy human subjects.
-
Altasciences Completes Clinical Portion of Alzamend Neuro’s Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer’s
4/18/2023
Altasciences is proud to support Alzamend Neuro, Inc. (Alzamend) in advancing a novel treatment for dementia related to Alzheimer’s disease (Alzheimer’s).
-
Audax Private Equity Announces Growth Investment in Pyramid Laboratories, Inc.
4/18/2023
Audax Private Equity (“Audax”), a leading alternative investment manager and capital partner, announced today that it has made a growth investment in Pyramid Laboratories, Inc. (“Pyramid” or the “Company”) to support the continued growth of the Company’s clinical and commercial biologics and advanced therapeutics manufacturing and service operations.
-
Altasciences Selects Proscia To Accelerate The Development Of Life-Saving Drugs
3/21/2023
Proscia®, a leading provider of digital and computational pathology solutions, today announced that Altasciences, a forward-thinking contract research organization (CRO), has chosen Concentriq® for Research to help its sponsors get life-saving therapeutics to patients sooner.
-
Virpax Pharmaceuticals Reports 2022 Third Quarter Results
11/9/2022
Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX) a company specializing in developing non-addictive product candidates for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the quarter ended September 30, 2022, and other recent developments.
-
Altasciences Expands Strategic Support for Early Drug Development in Europe and Adds Key Employees to Its Preclinical Team in North America
10/14/2022
Altasciences hired two expert advisors to support its strategic growth in Europe, while its preclinical team continues to expand with the addition of two key employees.
-
Jyoti Mundra, PhD, appointed as new Chief Business Officer at MEDSIR
9/22/2022
MEDSIR, an international company specialized in the strategic design of clinical trials is pleased to announce the appointment of Jyoti Mundra, PhD, as Chief Business Officer.
-
Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke
9/20/2022
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with Altasciences, a fully integrated early phase CRO/CDMO, to develop and manufacture the HT-TBI drug product formulation.
-
The possible addition of a new lithium-based drug to the list of available therapeutics is important because many physicians are reluctant to prescribe lithium.
-
TFF Pharmaceuticals Announces Safety and Pharmacokinetic Data from Phase 1 Study of Niclosamide Inhalation Powder
4/19/2022
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced safety and pharmacokinetic (PK) data from its Phase 1 study of Niclosamide Inhalation Powder, which is being developed for the treatment of COVID-19.
-
Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimer’s
4/11/2022
Alzamend Neuro, Inc. today announced that it contracted with Altasciences Clinical Kansas (“ Altasciences ”) and iResearch Atlanta, LLC (“iResearch”) to manage and conduct, respectively, its Phase IIA multiple ascending dose (“MAD”) study in patients with mild to moderate Alzheimer’s Disease (“Alzheimer’s”).
-
Virpax Pharmaceuticals Reports 2021 Year-End Results
3/31/2022
Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the twelve months ended December 31, 2021, and other recent developments.